Register Now

Overview

Join a presentation from one of your peers on the efficacy, safety, dosing, and administration of once-weekly Zepbound®. Learn about how to get appropriate patients started on this treatment. Attendees will have the opportunity to ask questions at the conclusion of the program. Refreshments will be provided.

This program is sponsored by, and the speaker is presenting on behalf of, Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit.

Please see Full Prescribing Information including Boxed Warning and Medication Guide at the product theater or on https://zepbound.lilly.com.

Zepbound® and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

Program Objectives
Upon completion of the program, participants will have learned the following about Zepbound:
Mechanism of action
Clinical trial data, including efficacy and safety findings
Dosing and administration information
How to get appropriate patients started

Program objectives as follows:

Upon completion of this program, participants will have learned:

- The disease state of obesity
- How to diagnose and assess for excess adiposity
- Understand management options including lifestyle changes, pharmacotherapy and bariatric surgery
- Using the 5As model to facilitate obesity counselling

SPONSORED BY

Eli Lilly & Company